Topic Editors

1. Associate Laboratory i4HB—Institute for Health and Bioeconomy, University Institute of Health Sciences—CESPU, 4585-116 Gandra, Portugal
2. ALiCE—Associate Laboratory in Chemical Engineering, Faculty of Engineering, LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Porto, Portugal
Division of Microbiology & NCDs, ICMR-Regional Medical Research Centre, Bhubaneswar 751023, India

Natural Products to Fight Fungal Infections

Abstract submission deadline
30 November 2025
Manuscript submission deadline
30 December 2025
Viewed by
1902

Topic Information

Dear Colleagues,

Fungal infections are a growing global threat as they are becoming increasingly resistant to antifungal drugs, thus resulting in rising hospital costs and mortality. According to World Health Organization (WHO) reports, 19 fungi are on the WHO priority pathogen list, and researchers argue that more research is needed to fight these pathogens. Fungal infections are no longer limited to a single geographical region but have spread globally as a result of global warming, international travel, and trade. Mostly, people with cancer, HIV/AIDS, organ transplants, chronic respiratory disease, tuberculosis infection, etc., have a higher risk of invasive fungal infection. As per the present incidence rate and clinical indications, it is predictable that 10 million people die per year because of emerging multidrug resistant fungal species such as Candida, Aspergillus, Cryptococcus, or Pneumocystis. Therefore, newer regimens are urgently needed to tackle these pathogens. Natural compounds are a suitable alternative to use as monotherapy and combined therapy. Reports show that a large number of natural products (e.g., phytochemicals and marine derived compounds) are effective against various fungal species. Alkaloids, polyphenols, steroids, glycosides, and tarpenoids contain unique chemical fractions that prevent or inhibit infections through the reduction in oxidative stress, inhibition, and enzymatic activation and the modulation of the expression of certain genes. In addition, in silico methods may be effective against a target enzyme, and the present in silico platforms are more reliable to locate the most likely active candidate with limited resources and time. As a result, most pharmaceutical and academic research employ various in silico or bioinformatics tools to identify the most promising candidates at the preliminary stage and then move forward with that potent candidate for further in vitro and in vivo studies. This Topic Issue covers the state of novel treatments related to fungal infections through natural compounds. Mainly, it aims to collect basic and translational discoveries and findings on potential antifungal natural compounds using in silico, in vitro, and in vivo methods. The evaluation and validation of new bioactive molecules against fungal pathogens with multidrug resistance patterns are also welcome. In addition, review manuscripts on the gathering and critical analysis of huge sets or databases on natural products for future antifungal drug development are also opportune to be covered in this Topic Issue.

Dr. Célia Fortuna Rodrigues
Dr. Shasank Sekhar Swain
Topic Editors

Keywords

  • fungal infection
  • candida
  • aspergillus
  • cryptococcus
  • natural antifungal candidate
  • drug resistance
  • in silico and in vitro studies
  • molecular docking and simulation
  • toxicity and pharmacokinetics profiles

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomedicines
biomedicines
3.9 5.2 2013 14.6 Days CHF 2600 Submit
Journal of Fungi
jof
4.2 6.7 2015 17.7 Days CHF 2600 Submit
Pharmaceuticals
pharmaceuticals
4.3 6.1 2004 13.9 Days CHF 2900 Submit
Pharmaceutics
pharmaceutics
4.9 7.9 2009 15.5 Days CHF 2900 Submit
Reports
reports
0.8 - 2018 18.6 Days CHF 1400 Submit
Molecules
molecules
4.2 7.4 1996 15.1 Days CHF 2700 Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
15 pages, 2618 KiB  
Article
The Antifungal Effects of Equol Against Candida albicans Involve Mitochondrial Dysfunction
by Anni Ge, Hao Zhou, Xi Yang, Chunling Zhao, Caiyan Xin and Zhangyong Song
J. Fungi 2025, 11(5), 339; https://doi.org/10.3390/jof11050339 - 27 Apr 2025
Viewed by 53
Abstract
Novel antifungal agents are urgently needed because of the increasing number of drug-resistant Candida strains encountered in clinical practice and the limited variety of available antifungal drugs. Equol, a metabolite of soy isoflavone glycosides, exhibits antifungal activities. In this study, Equol had good [...] Read more.
Novel antifungal agents are urgently needed because of the increasing number of drug-resistant Candida strains encountered in clinical practice and the limited variety of available antifungal drugs. Equol, a metabolite of soy isoflavone glycosides, exhibits antifungal activities. In this study, Equol had good inhibitory activity against Candida species. The lowest inhibitory concentration of 125–500 μg/mL was confirmed by the gradient dilution method. In addition, transmission electron microscopy and the relative content assay showed that Equol altered the cell wall and membrane of Candida albicans. Further studies found that Equol treatment increased the intracellular levels of reactive oxygen species and Ca2+. Subsequent experiments suggested that Equol treatment depolarized the membrane potential of C. albicans and up-regulated the expression of the apoptosis-inducing factor gene. These results confirmed that Equol damaged the cell wall and membrane, dysregulated the intracellular components, induced oxidative stress and Ca2+ accumulation, and ultimately resulted in mitochondrial dysfunction. Collectively, these findings demonstrated that Equol is a potential antifungal agent. Full article
(This article belongs to the Topic Natural Products to Fight Fungal Infections)
Show Figures

Figure 1

Back to TopTop